OG‘IR TIZIMLI OSTEOPOROZDA PERIPROTEZ SON SUYAGI SINISHINI JARROHLIK VA ANTIOSTEOPOROTIK DAVOLASH NATIJALARI
Keywords:
og‘ir osteoporoz, estrogen yetishmovchiligi, jarrohlik menopauzasi, periprotez sinish, son suyagiAbstract
Maqolada og‘ir tizimli osteoporoz fonida chanoq-son bo‘g‘imi endoprotezidan keyin yuzaga kelgan periprotez son suyagi sinishini jarrohlik va antiosteoporotik davolash natijalari klinik holat asosida tahlil qilindi. Klinik kuzatuvda anamnestik ma’lumotlarga ko‘ra tuxumdonlar olib tashlanganidan keyingi uzoq muddatli estrogen yetishmovchiligi, og‘ir osteoporoz, avval bajarilgan ikki tomonlama endoprotezlash va revizion operatsiyalar, shuningdek kam energiyali travmadan keyin ikki tomonlama periprotez sinishlar yuzaga kelishi o‘zaro bog‘liq patogenetik jarayon sifatida baholandi. Davolashda protez barqarorligi, sinish chizig‘ining joylashuvi, suyak sifati va bemorning umumiy somatik holati inobatga olindi. Jarrohlik bosqichida son suyagi plastina bilan ekstramedullyar osteosintez qilindi, operatsiyadan keyingi davrda esa kalsiy, vitamin D3, bisfosfonat va denosumab asosidagi antiosteoporotik terapiya tavsiya etildi. Kuzatuvda yara birlamchi bitishi, rentgenologik jihatdan suyak bo‘laklari turishining qoniqarli bo‘lishi va 6 oyda bemorning mustaqil yurishga erishgani qayd etildi. Klinik holat periprotez sinishlarda faqat mexanik fiksatsiya emas, balki osteoporozning metabolik-gormonal sabablarini aniqlash va korreksiya qilish davolash natijasini belgilovchi muhim omil ekanini ko‘rsatadi.
Downloads
References
1. Duncan C.P., Masri B.A. Fractures of the femur after hip replacement // Instructional Course Lectures. - 1995. - Vol. 44. - P. 293-304.
2. Gaski G.E., Scully S.P. Classifications in brief: Vancouver classification of postoperative periprosthetic femur fractures // Clinical Orthopaedics and Related Research. - 2011. - Vol. 469, No. 5. - P. 1507-1510.
3. Marsland D., Mears S.C. A review of periprosthetic femoral fractures associated with total hip arthroplasty // Geriatric Orthopaedic Surgery & Rehabilitation. - 2012. - Vol. 3, No. 3. - P. 107-120.
4. Kanis J.A., Johnell O., Oden A., Johansson H., McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK // Osteoporosis International. - 2008. - Vol. 19. - P. 385-397.
5. Schini M., Johansson H., Harvey N.C., et al. An overview of the use of the fracture risk assessment tool FRAX in osteoporosis // Archives of Osteoporosis. - 2024. - Vol. 19. - Article 41.
6. Camacho P.M., Petak S.M., Binkley N., et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2020 update // Endocrine Practice. - 2020. - Vol. 26, Suppl. 1. - P. 1-46.
7. Shoback D., Rosen C.J., Black D.M., et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update // Journal of Clinical Endocrinology & Metabolism. - 2020. - Vol. 105, No. 3. - P. 587-594.
8. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis // New England Journal of Medicine. - 2007. - Vol. 356. - P. 1809-1822.
9. Cummings S.R., San Martin J., McClung M.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis // New England Journal of Medicine. - 2009. - Vol. 361. - P. 756-765.
10. Black D.M., Rosen C.J. Postmenopausal osteoporosis // New England Journal of Medicine. - 2016. - Vol. 374. - P. 254-262.
11. Khosla S., Oursler M.J., Monroe D.G. Estrogen and the skeleton // Trends in Endocrinology & Metabolism. - 2012. - Vol. 23, No. 11. - P. 576-581.
12. Watts N.B. The fracture risk assessment tool (FRAX): applications in clinical practice // Journal of Women’s Health. - 2011. - Vol. 20, No. 4. - P. 525-531.
13. FRAXplus®. Fracture Risk Assessment Tool. URL: https://www.fraxplus.org/ (murojaat sanasi: 11.06.2026).
